/
Oncology
Solid Tumor, Adult
31
Pipeline Programs↗
33
Active Trials↗
33
Companies Involved↗
Solid Tumor, Adult is a moderately active landscape with 31 programs across 33 companies. The most active players are CytomX Therapeutics, Monopar Therapeutics, Johnson & Johnson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 122
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
65%
Small molecule
17 of 26 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 94% of 31 pipeline programs.
Analysis
Trial Status
46
clinical trials
Active, not recruiting17 · 37%
Recruiting14 · 30%
Completed10 · 22%
Suspended2 · 4%
Not yet recruiting2 · 4%
Terminated1 · 2%
Clinical Trials
Trial Activity
46 trials
An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors
Recruiting·—·Phase 1·NCT05856981·130 enrolled
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)
Active, not recruiting·—·Preclinical·NCT07153094·47 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)